Deep-pocketed investors have adopted a bullish approach towards NuScale Power SMR, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

Whales with a lot of money to spend have taken a noticeably bearish stance on Zillow Gr. Looking at options history for Zillow Gr Z we detected 19 trades. If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 63% ...

Shares of Sony ( NYSE: SONY ) are seeing strong bullish momentum in Thursday's trading. The Japanese tech giant's share price was up 6% as of 12:30 p.m. ET today and had been up as much as 9.4% earlier in the day.Before the market opened this morning, Sony published results for the third quarter ...

EEFT's Q4 results benefit from strength in its three segments, attributable to higher transactions. It currently expects 2025 adjusted EPS to witness 12-16% year-over-year growth.

SAN DIEGO, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Kratos Defense & Security Solutions, Inc. ( NASDAQ: KTOS ) , a Technology Company in the Defense, National Security and Global Markets, announced today that it will publish financial results for the fourth quarter and fiscal year 2024 after the ...

RYE, N.Y., Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- The Board of Directors of The Gabelli Multimedia Trust Inc. ( NYSE:GGT ) ( the "Fund" ) reaffirmed and satisfied its 10% distribution policy by declaring a $0.22 per share cash distribution payable on March 24, 2025 to common stock shareholders of ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

FirstFarms A/S ( "FirstFarms" ) has today received a notification from Constantinsborg A/S ( the "Lender" ) regarding notice about conversion of a convertible bond with a principal amount of DKK 89,100,000 as well as accrued interest ( excluding interests already due and paid ) ( the "Loan ...

Moleculin Biotech stock surged on high volume after FDA guidance allowed a 10% reduction in its Phase 3 trial for Annamycin. The MIRACLE Phase 3 study's first unblinding at 45 subjects is expected in H2 2025, with the second unblinding in H1 2026.

GE HealthCare Q4 adjusted EPS rose to $1.45, surpassing the $1.26 consensus, with revenue of $5.32B, up 2% year-over-year. 2025 guidance projects 2%-3% organic revenue growth, adjusted EPS of $4.61-$4.75, and at least $1.75B in free cash flow.